MAUDE Adverse Event Report: Terumo Philippines Corporation SurGuard3 Safety Hypodermic Needle; NEEDLE, HYPODERMIC, SINGLE LUMEN

Model Number	SG3+2213
Medical Device Problem Code	Adverse Event Without Identified Device or Use Problem (2993)
Health Effect - Clinical Codes	Cellulitis (1768); Injection Site Reaction (4562)
Type of Reportable Event	Serious Injury
Event or Problem Description
Terumo received the following information: it was reported that a healthcare professional in the united states reported that after administration of yeztugo, the patient developed cellulitis at the injection site on the right mid-thigh, measuring 9 cm.The reporter stated that the needles and syringes were utilized from the gilead box.The reporter stated that "patient was injected per prescribing orders.The left thigh was not affected.Additional information received 17-sept-2026: the patient was treated for cellulitis with keflex (cephalexin) 500 mg orally four times daily for 7 days.
Additional Manufacturer Narrative
B3: date of event: unknown.D6a: implanted date: device was not implanted.D6b: explanted date: device was not explanted.E3: occupation: director of regulatory affairs.The actual device was not available for evaluation; therefore, we were unable to determine the details of the actual condition.Retention samples were visually inspected and found to be free from foreign material and any other contributing defects that could have led to the complaint.There was no issued nonconformity report related to human error during the production lot.Our sg needles were assembled using an automated machine with validated parameters.During the needle assembly process, the needles are adhered to the hub with an adhesive agent and lubricant for smooth needle penetration.This is done by dipping the needle into a tray with silicone.We have an air-blowing process to remove silicone inside the cannula during dipping.After this process, the needles will again pass through a series of air blowing to ensure the removal of any remaining excess silicone.We have an automatic needle tip inspection system during needle assembly that can detect and automatically reject damaged needle tips more than 40 micrometer.Dummy checks are performed on these sensors twice a week to ensure the accuracy of the inspection system.Our product's stainless needle is coated with a lubricant and adhered to the device using a highly viscous adhesive or bonding agent.The device is non-toxic and does not contain any toxins or harmful substances that are poisonous and does not contain components made of natural rubber latex.It is also pyrogen-free and therefore does not contain any drug impurity that, when injected into the bloodstream, may cause fever.The sg3 needle is individually packed in a blister to keep the product sterile.Our products meet iso 7864 standards, including limits for acidity, alkalinity, and extractable metals.We comply with the requirements of iso 10993 for testing and determining the biocompatibility of the needles.During the cannula inspection, the supplied cannula raw material has undergone an overall inspection.Defective samples found will be segregated and discarded accordingly.If any unusual cannula condition is found, a nonconformity report shall be issued.No nonconformity report was noted on the involved cannula lots.Qc conducts monthly physical and chemical tests on sterile products using the physicochemical test.The test items include acidity/alkalinity tests, extractable metals, and metal traces such as cadmium, lead, iron, zinc, and tin.Visual in-process inspections are conducted during the manufacturing process to inspect for burrs or bent points, tip damage, and foreign material in the product.We perform the cannula penetration test during needle assembly and the dental dam test during the sg assembly process to check the condition of the needle tip.Our finished products undergo bacterial endotoxin level testing to ensure they are free of bacterial endotoxin.All finished products undergo electron beam sterilization.The absorbed dose is measured for every sterilization batch.As part of our microbiological testing, sterility tests were conducted on our sg3 products every quarter.Additionally, a stability test inspection was performed, which included an annual sterility test starting from the production date until the fifth year.We have set cleaning frequencies in the area, including machines, tools, and equipment, to ensure the cleanliness and quality of products.We perform product confirmation when changes are made in the machine, such as machine start-up, after machine maintenance, after machine adjustment/troubleshooting, after power fluctuation, after validation/sampling, lot change/type change, and after machine cleaning, to ensure that the product is in good condition.Before shipment, qc conducts outgoing inspections to check the overall condition of the products.The supplied cannula raw material is tpc inspected, wherein the overall visual condition of the cannula has been checked.No nonconformity was noted on the records.From the previous two fiscal years to the present, we received a total of 35 adverse event out of 36 injection site reaction complaints.The cause of these complaints was not identified as being related to our product or the manufacturing process.Based on the results of our investigation, the root cause of the complaint is not related to our product or production process.Our sg3 needle is non-toxic and does not contain any toxins or poisonous substances.It is also free of pyrogens, which means it contains no substances that can cause fever when injected into the bloodstream.The retention samples were visually inspected and confirmed to be free from foreign material and any other contributing defects that could have led to the complaint.Every lot is tested for the presence of bacterial endotoxin to ensure that our products are safe to use and will not cause any harm.We also have monthly physicochemical tests to check for metal and alkaline traces.Cleanliness is maintained inside the production area to ensure that the products are free from foreign material contamination.All finished products are sterilized using the electron beam sterilization process, and qc performs outgoing inspection before shipment to ensure the overall condition of the needles.Additionally, sterility tests are conducted quarterly for microbiological testing and annually for stability test inspections.These confirm the effectiveness of our sterilization process.Terumo medical corporation (tmc) (importer) registration no.2243441 is submitting this report on behalf of terumo (philippines) corporation (manufacturer) registration no.3003902955.

• Brand Name: SurGuard3 Safety Hypodermic Needle
• Common Device Name: NEEDLE, HYPODERMIC, SINGLE LUMEN
• Manufacturer (Section D): Terumo Philippines Corporation; 124 east main avenue; laguna technopark; biñan laguna, 4024 ; RP 4024
• Manufacturer (Section G): Terumo Philippines Corporation; 124 east main avenue; laguna technopark; biñan laguna, 4024 ; RP 4024
• Manufacturer Contact: stephanie handy ; 950 elkton blvd.; elkton, MD 21921 ; +1(949)989-0491
• MDR Report Key: 50919150
• Report Number: 3003902955-2026-00093
• Device Sequence Number: 5777080
• Product Code: FMI
• UDI-Device Identifier: 14806017510746
• Combination Product (Y/N): N
• Initial Reporter State: CA
• Initial Reporter Country: US
• PMA/510(K) Number: K152362
• Number of Events Summarized: 1
• Summary Report (Y/N): N
• Serviced by Third Party (Y/N): N
• Reporter Type: Manufacturer
• Report Source: User Facility,Company Representative
• Initial Reporter Occupation: Non-Healthcare Professional
• Type of Report: Initial
• Report Date (Section B): 09/28/2026

1 Device was Involved in the Event

1 Patient was Involved in the Event

• Is this an Adverse Event Report?: Yes
• Is this a Product Problem Report?: Yes
• Operator of Device: Health Professional
• Device Model Number: SG3+2213
• Device Catalogue Number: N/A
• Device Lot Number: 250110C
• Was Device Available for Evaluation?: No
• Is the Reporter a Health Professional?: No
• Type of Report(Section G): Thirty-Day
• Initial Date Received by Manufacturer: 09/03/2026
• Initial Report FDA Received Date: 09/28/2026
• Was Device Evaluated by Manufacturer? (Y/N): No
• Date Device Manufactured: 01/10/2025
• Is the Device Labeled for Single Use? (Y/N): Yes
• Is This a Single-Use Device that was Reprocessed and Reused on a Patient? (Y/N): No
• Usage of Device: Initial
• Patient Sequence Number: 1
• Concomitant Medical Products and Therapy/Usage Dates: Yeztugo Injection.
• Outcome Attributed to Adverse Event: Required Intervention
• Patient Age: 34 YR
• Patient Sex: Male